You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 6,013,620

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,013,620

Title:	Pharmaceutical composition for the treatment of blood coagulation diseases, methods for the production thereof and its use
Abstract:	The invention relates to a pharmaceutical composition for the treatment of patients with blood coagulation diseases which are caused by coagulation factor deficiency and/or inhibitors of coagulation factors, whereby the composition as a FEIB-activity and is characterized in that it has Factor VIIa and at least one further active ingredient and the activity of at least 10 Factor VIIa units per unit FEIBA. Additionally, the invention comprises a method for the production of the pharmaceutical preparation and its use.
Inventor(s):	Turecek; Peter (Klosterneuburg, AT), Schwarz; Hans-Peter (Vienna, AT), Redl; Gerda (Rutzendorf, AT)
Assignee:	Baxter Aktiengesellschaft (Vienna, AT)
Application Number:	08/926,845
Patent Claims:	1. A method for producing a composition having a Factor VIII Inhibitor Bypassing Activity (FEIBA) of at least 5 U/ml and a Factor VIIa activity of at least 10 units FEIBA, comprising: contacting a Factor VII-containing fraction with an anion exchanger, wherein the Factor VII is at least partially activated, isolating a fraction containing activated Factor VII, wherein the fraction has FEIBA, and producing from said isolated fraction a composition having a Factor VIII Inhibitor Bypassing Activity (FEIBA) of at least 5 U/ml and a Factor VIIa activity of at least 10 units FEIBA. 2. A method according to claim 1, wherein the anion exchanger comprises quaternary ammonium groups. 3. A method according to claim 2, wherein the anion exchanger comprises an anion exchange moiety selected from the group consisting of quaternary aminoethyl, trimethylaminoethyl and quaternary ammonium. 4. A method according to claim 1, wherein Factor VIIa is isolated by hydrophobic chromatography. 5. The method according to claim 1, wherein the composition has an activity of 10 to 100 Factor VIIa units per unit FEIBA. 6. The method according to claim 5, wherein the composition has an activity of 10 to 20 Factor VIIa units per unit FEIBA. 7. The method according to claim 6, wherein the composition has an activity of 10 to 15 Factor VIIa units per unit FEIBA. 8. The method according to claim 1, wherein the composition further comprises a blood protein selected from the group consisting of Factor II, Factor IX, Factor IXa, Factor X and Factor Xa, wherein the blood protein is present in a range of 0.5 to 2 units per unit FEIBA. 9. The method according to claim 8, wherein the blood protein is present in a range of 0.5 to 1.5 units per unit FEIBA. 10. The method according to claim 8, further comprising adding a blood protein selected from the group consisting of Factor II, Factor IX, Factor IXa, Factor X and Factor Xa, such that the blood protein is present in the composition in a range of 0.5 to 2 units per unit FEIBA. 11. The method according to claim 10, wherein the blood protein is present in a range of 0.5 to 1.5 units per unit FEIBA. 12. A method according to claim 1, wherein the composition is a pharmaceutical composition. 13. A method for producing a composition having a Factor VIII Inhibitor Bypassing Activity (FEIBA) of at least 5 U/ml and a Factor VIIa activity of at least 10 units per unit FEIBA, comprising: combining a Factor VII-containing fraction, wherein the Factor VII is at least partially activated, with coagulation Factors II, IX and X, and obtaining a composition having a Factor VIII Inhibitor Bypassing Activity (FEIBA) of at least 5 U/ml and a Factor VIIa activity of at least 10 units FEIBA. 14. A method according to claim 13, further comprising treating the coagulation Factors to inactivate infectious agents. 15. A method according to claim 14, wherein the treating occurs after combining. 16. A method according to claim 14, wherein the treating occurs before combining. 17. A method according to claim 14, wherein the treating employs heat. 18. A method according to claim 17, wherein the coagulation Factors are in a solid state. 19. A method according to claim 17, wherein the heat treatment occurs in the absence of albumin. 20. A method according to claim 13, wherein Factor VII is isolated using anion exchange chromatography, thereby at least partially activating the Factor VII. 21. A method according to claim 13, wherein Factor IX and Factor X are isolated using anion exchange chromatography, thereby at least partially activating Factor IX and Factor X. 22. The method according to claim 13, wherein the composition has an activity of 10 to 100 Factor VIIa units per unit FEIBA. 23. The method according to claim 22, wherein the composition has an activity of 10 to 20 Factor VIIa units per unit FEIBA. 24. The method according to claim 23, wherein the composition has an activity of 10 to 15 Factor VIIa units per unit FEIBA. 25. A method according to claim 13, wherein the composition is a pharmaceutical composition.

Details for Patent 6,013,620

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	12/21/1979	⤷ Try a Trial	2015-08-28
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	07/31/2000	⤷ Try a Trial	2015-08-28
Baxalta Us Inc.	AUTOPLEX, FEIBA NF, FEIBA VH	anti-inhibitor coagulant complex	For Injection	101447	08/11/2005	⤷ Try a Trial	2015-08-28
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.